Table. 1.
Control | αGPIb | DDAVP | αGPIb + DDAVP | αGPIIb/IIIa | αGPIb + αGPIIb/IIIa | |
---|---|---|---|---|---|---|
Total (n) | 37 | 6 | 6 | 6 | 6 | 4 |
Failed lungs (n) | 27 | 3 | 1 | 1 | 5 | 3 |
Rejection reason | n (%) of failed lungs | |||||
---|---|---|---|---|---|---|
Trachea edema | 7 (19%) | 2 (33%) | - | - | 1 (17%) | 1 (25%) |
Loss of perfusate | 2 (5%) | - | - | - | - | - |
Loss of blood flow | 15 (41%) | 1 (17%) | 1 (17%) | 1 (17%) | 4 (67%) | 2 (50%) |
Oxygen failure | 3 (8%) | - | - | - | - | - |
The table shows that the loss of blood flow through the lungs (elevated pulmonary vascular resistance) was the predominant lung failure mechanism, followed by the development of trachea edema.
DDAVP, desmopressin (1-desamino-8-d-arginine vasopressin).